{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:53:23Z","timestamp":1792180403759,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5NU2RGH001913-05-00"],"award-info":[{"award-number":["5NU2RGH001913-05-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2021.04.061","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:56:01Z","timestamp":1620946561000},"page":"A136-A141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S1","title":["Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response"],"prefix":"10.1016","volume":"41","author":[{"given":"Dominika A.","family":"Kalkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.F.","family":"Wassilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Cochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.04.061_b0005","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1539-6924.2006.00843.x","article-title":"Evaluation of response scenarios to potential polio outbreaks using mathematical models","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.061_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2334-14-45","article-title":"The potential impact of expanding target age groups for polio immunization campaigns","volume":"14","author":"Duintjer Tebbens","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0015","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/infdis\/jiu674","article-title":"Modeling options to manage type 1 wild poliovirus imported into Israel in 2013","volume":"211","author":"Kalkowska","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0025","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1073\/pnas.1323688111","article-title":"The role of older children and adults in wild poliovirus transmission","volume":"111","author":"Blake","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2021.04.061_b0030","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-016-1537-8","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-016-1536-9","article-title":"Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0045","first-page":"190","article-title":"The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation","volume":"10","author":"Thompson","year":"2008","journal-title":"Med J Med"},{"key":"10.1016\/j.vaccine.2021.04.061_b0050","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1016\/j.vaccine.2010.04.001","article-title":"Optimal vaccine stockpile design for an eradicated disease: Application to polio","volume":"28","author":"Duintjer Tebbens","year":"2010","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.04.061_b0055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14760584.2017.1322514","article-title":"Poliovirus vaccination during the endgame: Insights from integrated modeling","volume":"16","author":"Duintjer Tebbens","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.061_b0060","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2018.1506333","article-title":"Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine","volume":"17","author":"Duintjer Tebbens","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.061_b0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.04.061_b0070","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jix128","article-title":"Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.061_b0080","first-page":"15","article-title":"The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission","author":"Thompson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0085","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Duintjer Tebbens","year":"2018","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.061_b0090","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Duintjer Tebbens","year":"2006","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.061_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-020-0176-7","article-title":"Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization","volume":"5","author":"Konopka-Anstadt","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.061_b0100","unstructured":"World Health Organization Global Polio Eradication Initiative. Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020\u20132021: Addendum to the Polio eradication and endgame strategic plan (2019-2023). http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf. 2020 [accessed Mar 10, 2020]."},{"key":"10.1016\/j.vaccine.2021.04.061_b0105","first-page":"15","article-title":"An economic analysis of poliovirus risk management policy options for 2013\u20132052","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.061_b0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4172\/2157-7560.1000339","article-title":"Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management","volume":"7","author":"Duintjer Tebbens","year":"2016","journal-title":"J Vaccines Vaccination"},{"key":"10.1016\/j.vaccine.2021.04.061_b0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14760584.2019.1635463","article-title":"Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)","volume":"18","author":"Thompson","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.061_b0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/risa.13447","article-title":"Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.061_b0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of poliovirus outbreak response strategies for 2019\u20132029: Impacts of the use of novel OPV2 strains","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.061_b0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/risa.13590","article-title":"Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2021.04.061_b0135","article-title":"The impact of disruptions caused by the COVID-19 pandemic on global polio eradication","author":"Kalkowska","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.061_b0140","unstructured":"World Health Organization. Novel oral polio vaccine type 2 (nOPV2) granted EUL recommendation. https:\/\/polioeradication.org\/news-post\/novel-oral-polio-vaccine-type-2-nopv2-granted-interim-emergency-use-listing-recommendation\/, 2020. [accessed Nov 15, 2020]."},{"key":"10.1016\/j.vaccine.2021.04.061_b0145","unstructured":"Global Polio Eradication Initiative. Implementation of nOPV2 for cVDPV2 outbreak response: Technical guidance for countries. http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/12\/nOPV2-Technical-Guidance-20201210.pdf. 2020 [accessed Mar 4, 2021]."},{"key":"10.1016\/j.vaccine.2021.04.061_bib146","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab160","article-title":"Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options","author":"Kalkowska","year":"2021","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:11Z","timestamp":1759404251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21005430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":30,"alternative-id":["S0264410X21005430"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}